Insulin degludec
- Generic Name
- Insulin degludec
- Brand Names
- Ryzodeg, Tresiba, Xultophy
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 844439-96-9
- Unique Ingredient Identifier
- 54Q18076QB
- Background
Insulin degludec is an ultra-long-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Insulin is typically prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide hormone produced by beta cells of the pancreas that promotes glucose metabolism. ...
- Indication
Insulin degludec is indicated to improve glycemic control in patients 1 year of age and older with diabetes mellitus.
- Associated Conditions
- Diabetes Mellitus, Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
- Associated Therapies
- -
A Study of LY900014 Compared to Insulin Lispro (Humalog) in Adults With Type 2 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2019-05-16
- Last Posted Date
- 2022-02-08
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 628
- Registration Number
- NCT03952143
- Locations
- 🇨🇳
Dalian Municipal Central Hospital Affiliated of Dalian Medical University, Dalian, Cn-21, China
🇨🇳Shengjing Hospital of China Medical University, Shenyang, Cn-21, China
🇨🇳Shanghai Putuo District Center Hospital, Shanghai, Cn-31, China
A Study of LY900014 Compared to Insulin Lispro (Humalog) in Adults With Type 1 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2019-05-16
- Last Posted Date
- 2023-02-08
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 354
- Registration Number
- NCT03952130
- Locations
- 🇦🇷
Centro Médico Viamonte, Caba, Buenos Aires, Argentina
🇦🇷Cent Priva Especiali Médicas Ambulatorias Inve Clin CEMAIC, Cordoba, Argentina
🇨🇳Dongguan people's hospital, Dongguan, Guangdong, China
A Study of Tirzepatide (LY3298176) Versus Insulin Degludec in Participants With Type 2 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2019-03-20
- Last Posted Date
- 2022-01-19
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 1444
- Registration Number
- NCT03882970
- Locations
- 🇺🇸
Valley Clinical Trials, Inc., Northridge, California, United States
🇺🇸National Research Institute, Panorama City, California, United States
🇺🇸Catalina Research Institute, LLC, Montclair, California, United States
Remission Evaluation of a Metabolic Intervention for Type 2 Diabetes With IDegLira
- Conditions
- Interventions
- First Posted Date
- 2019-03-05
- Last Posted Date
- 2023-10-25
- Lead Sponsor
- Population Health Research Institute
- Target Recruit Count
- 159
- Registration Number
- NCT03862716
- Locations
- 🇨🇦
University of Alberta, Edmonton, Alberta, Canada
🇨🇦McMaster University, Hamilton, Ontario, Canada
🇨🇦Western University, London, Ontario, Canada
Flexible Insulin Therapy Untethered Insulin Regimen in Avidly Exercising Patients With Type 1 Diabetes: FIT Untethered
- First Posted Date
- 2019-02-12
- Last Posted Date
- 2019-02-12
- Lead Sponsor
- LMC Diabetes & Endocrinology Ltd.
- Target Recruit Count
- 30
- Registration Number
- NCT03838783
- Locations
- 🇨🇦
LMC Diabetes & Endocrinology Ltd., Toronto, Ontario, Canada
A Research Study, Looking at How Tresiba® Works in People With Type 2 Diabetes in Local Clinical Practice in Saudi Arabia
- First Posted Date
- 2018-12-24
- Last Posted Date
- 2021-06-04
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 597
- Registration Number
- NCT03785522
- Locations
- 🇸🇦
Novo Nordisk Investigational Site, Riyadh, Saudi Arabia
A Study Comparing LY900014 to Insulin Lispro (Humalog) in Children and Adolescents With Type 1 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2018-11-14
- Last Posted Date
- 2022-01-24
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 751
- Registration Number
- NCT03740919
- Locations
- 🇺🇸
Rocky Mountain Diabetes and Osteoporosis Center, Idaho Falls, Idaho, United States
🇺🇸Children's Hospital Los Angeles - Dept of Endocrinology, Los Angeles, California, United States
🇺🇸University of Arizona, Tucson, Arizona, United States
A Study of LY3209590 in Participants With Type 2 Diabetes Mellitus
- Conditions
- Interventions
- First Posted Date
- 2018-11-09
- Last Posted Date
- 2021-03-08
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 399
- Registration Number
- NCT03736785
- Locations
- 🇺🇸
John Muir Physician Network Clinical Research Center, Concord, California, United States
🇺🇸Valley Endocrine, Fresno, Fresno, California, United States
🇺🇸National Research Institute, Los Angeles, California, United States
A Research Study to Compare the Effect of Insulin Degludec and Insulin Glargine on Blood Sugar Levels in People With Type 2 Diabetes - the SWITCH PRO Study
- Conditions
- Interventions
- First Posted Date
- 2018-09-27
- Last Posted Date
- 2021-01-12
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 498
- Registration Number
- NCT03687827
- Locations
- 🇿🇦
Novo Nordisk Investigational Site, Cape Town, Western Cape, South Africa
A Canadian Study of the Effectiveness of Tresiba® (Insulin Degludec) After Switching Basal Insulin in a Population With Type 1 or Type 2 Diabetes Mellitus
- Conditions
- Interventions
- First Posted Date
- 2018-09-18
- Last Posted Date
- 2019-12-06
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 662
- Registration Number
- NCT03674866
- Locations
- 🇨🇦
Novo Nordisk Investigational Site, Terrebonne, Quebec, Canada
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.